ArchiveJune 2017

What’s Torsades?

If you read the post below you may, like I, ask what is Torsades de pointes,  We know that fingolimod can cause heart arrhythmias on first dose. Torsades de pointes is another heart problem Torsades de pointes or torsade depointes (TdP or simply torsade(s)) translated as “twisting of the points”), is a specific type of abnormal heart...

Liver problem after generic glatiramer acetate: Cop Wars

Sabatino JJ Jr, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e368. Recently ProfG reported on a case of liver problems after daclizumab. This has happened after treatment with CRAB drugs and this is a case report of a new generic copaxone. It was reported that there the problem...

My drug is better than low hanging fruit. Rituximab better than CRAB

Spelman T, Frisell T, Piehl F, Hillert J.Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2017 Jun 1:1352458517713668. OBJECTIVE:To compare treatment effectiveness and persistence in relapsing-remitting multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or...

Blocking NOGO to make nerves

Ineichen BV, Kapitza S, Bleul C, Good N, Plattner PS, Seyedsadr MS, Kaiser J, Schneider MP, Zörner B, Martin R, Linnebank M, Schwab ME.Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology.Acta Neuropathol. 2017 doi: 10.1007/s00401-017-1745-3 Two hallmarks of chronic multiple sclerosis lesions are the absence of significant spontaneous...

Staggeringly profitable business of Science publishing

If you are interested in the publishing process you may want to read this. We have been telling you about the publication process and this article adds to the madness.  Is the staggeringly profitable business of scientific publishing bad for science? by Stephen Buranyi CLICK Here In addition to this, the Open access system has turned it all into a bottomless sink. Will it change…...

Blood NFL as marker of no evidence of disease activity with fingolimod

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod Fredrik Piehl, Ingrid Kockum, Mohsen Khademi, Kaj Blennow, Jan Lycke, Henrik Zetterberg, Tomas Olsson Multiple Sclerosis Journal, First Published 19 Jun 2017.doi: 10.1177/1352458517715132 Abstract Background: Neurofilament light chain (NFL) is a cerebrospinal fluid (CSF) marker of...

Questions for today’s Symposium

ProfG is at the European Neurology Meeting in Amsterdam. Today, there is a SANOFI GENZYME Satellite Symposium: From clinical data to real world experience – similar results, similar benefits for multiple sclerosis patients? I guess MS CARE extension data will be presented. The message will be alemtuzumab is a very good drug. The bad news will be that the proportion of people with secondary...

More fingolimod rebounds

Forci B, Mariottini A, Mechi C, Massacesi L, Repice A. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. Mult Scler Relat Disord. 2017 Jul;15:24-26. BACKGROUND:Severe multiple sclerosis reactivation following second line treatment withdrawal, defined “rebound syndrome”, is becoming a prominent issue to consider when deciding to...

The Burden of Multiple Sclerosis

This study examines the cost of MS in different European Countries if you go East the amount spent on people with MS is lower. However you can see that the costs are not harmonised across Europe.  In the UK the cost is low. Is this because of efficiency or are we near the bottom of the pile (yes you could add about 10-20%  to get a fairer view, because I used todays exchange rates)...

The ProfG’s need a kick up the backside. Publish trials

Stefaniak JD, Lam TCH, Sim NE, Al-Shahi Salman R, Breen DP. Discontinuation and non-publication of neurodegenerative disease trials: a cross-sectional analysis. Eur J Neurol. 2017. doi: 10.1111/ene.13336. [Epub ahead of print] BACKGROUND AND PURPOSE:Trial discontinuation and non-publication represent major sources of research waste in clinical medicine. No previous studies have investigated...

Translate

Categories

Recent Posts

Recent Comments

Archives